COLL
Collegium Pharmaceutical, Inc.NASDAQHealthcare$32.31-2.83%ClosedMarket Cap: $1.03B
As of 2026-04-06
Valuation
P/E (TTM)
16.32
PEG
—
P/B
3.43
P/S
1.33
EV/EBITDA
2.87
DCF Value
$675.75
FCF Yield
31.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.3%
Operating Margin
23.0%
Net Margin
8.1%
ROE
24.1%
ROA
3.8%
ROIC
9.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $205.4M | 62.5% | $59.2M | $17.0M | $0.46 | — |
| FY 2025 | $780.6M | 59.3% | $187.1M | $62.9M | $1.73 | — |
| Q3 2025 | $209.4M | 61.7% | $63.6M | $31.5M | $0.84 | — |
| Q2 2025 | $188.0M | 57.7% | $35.1M | $12.0M | $0.34 | — |
| Q1 2025 | $177.8M | 54.8% | $21.7M | $2.4M | $0.07 | — |
| Q4 2024 | $181.9M | 54.0% | $38.1M | $12.5M | $0.35 | — |
| FY 2024 | $631.4M | 59.8% | $169.9M | $69.2M | $1.86 | — |
| Q3 2024 | $159.3M | 60.8% | $34.8M | $9.3M | $0.27 | — |
| Q2 2024 | $145.3M | 62.5% | $47.5M | $19.6M | $0.52 | — |
| Q1 2024 | $144.9M | 63.1% | $49.5M | $27.7M | $0.71 | — |
| Q4 2023 | $149.7M | 63.2% | $61.7M | $31.9M | $0.82 | — |
| FY 2023 | $566.8M | 57.5% | $167.0M | $48.2M | $1.29 | — |